SEARCH

SEARCH BY CITATION

References

  • Baichwal VR and Sugden B (1988) Transformation of Balb 3T3 cells by the BNLF-1 gene of Epstein–Barr virus. Oncogene, 2, 461467.
  • Briscoe J, Kohlhuber F and Müller M (1996) JAKs and STATs branch out. Trends Cell Biol, 6, 336340.
  • Catlett-Falcone R et al. (1999) Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity, 10, 105115.
  • Cohen JI, Wang F and Kieff E (1991) Epstein–Barr virus nuclear protein 2 mutations define essential domains for transformation and transactivation. J Virol, 65, 25452554.
  • Darnell JE (1997) STATs and gene regulation. Science, 277, 16301635.
  • Delecluse H-J, Hilsendegen T, Pich D, Zeidler R and Hammerschmidt W (1998) Propagation and recovery of intact, infectious Epstein–Barr virus from prokaryotic to human cells. Proc Natl Acad Sci USA, 95, 82458250.
  • Delecluse H-J, Pich D, Hilsendegen T, Baum C and Hammerschmidt W (1999) A first generation packaging cell line for Epstein–Barr derived vectors. Proc Natl Acad Sci USA, in press.
  • Devergne O, Hatzivassiliou E, Izumi KM, Kaye KM, Kleijnen MF, Kieff E and Mosialos G (1996) Association of TRAF1, TRAF2 and TRAF3 with an Epstein–Barr virus LMP1 domain important forB-lymphocyte transformation: role in NF-κB activation. Mol Cell Biol, 16, 70987108.
  • Eliopoulos AG and Rickinson AB (1998) LMP1 masquerades as an active receptor. Curr Biol, 8, R196R198.
  • Eliopoulos AG and Young LS (1998) Activation of the cJun N-terminal kinase (JNK) pathway by the Epstein–Barr virus-encoded latent membrane protein 1 (LMP1). Oncogene, 16, 17311742.
  • Eliopoulos AG, Stack M, Dawson CW, Kaye KM, Hodgkin L, Sihota S, Rowe M and Young LS (1997) Epstein–Barr virus-encoded LMP1 and CD40 mediate IL-6 production in epithelial cells via an NF-κB pathway involving TNF receptor-associated factors. Oncogene, 14, 28992916.
  • Farrell PJ (1995) Epstein–Barr virus immortalizing genes. Trends Microbiol, 3, 105109.
  • Floettmann JE and Rowe M (1997) Epstein–Barr virus latent membrane protein-1 (LMP1) C-terminus activation region 2 (CTAR2) maps to the far C-terminus and requires oligomerisation for NF-κB activation. Oncogene, 15, 18511858.
  • Galibert L, Burdin N, de Saint-Vis B, Garrone P, Van Kooten C, Banchereau J and Rousset F (1996) CD40 and B cell antigen receptor dual triggering of resting B lymphocytes turns on a partial germinal center phenotype. J Exp Med, 183, 7785.
  • Gires O, Zimber-Strobl U, Gonnella R, Ueffing M, Marschall G, Zeidler R, Pich D and Hammerschmidt W (1997) Latent membrane protein 1 of Epstein–Barr virus mimics a constitutively active receptor molecule. EMBO J, 16, 61316140.
  • Graham FL, Smiley J, Russell WC and Nairn R (1977) Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol, 36, 5974.
  • Hammarskjold ML and Simurda MC (1992) Epstein–Barr virus latent membrane protein transactivates the human immunodeficiency virus type 1 long terminal repeat through induction of NF-κB activity. J Virol, 66, 64966501.
  • Hammerschmidt W and Sugden B (1989) Genetic analysis of immortalizing functions of Epstein–Barr virus in human B lymphocytes. Nature, 340, 393397.
  • Hanissian SH and Geha RS (1997) Jak3 is associated with CD40 and is critical for CD40 induction of gene expression in B cells. Immunity, 6, 379387.
  • Hatzivassiliou E, Miller WE, Raab-Traub N, Kieff E and Mosialos G (1998) A fusion of the EBV latent membrane protein-1 (LMP1) transmembrane domains to the CD40 cytoplasmic domain is similar to LMP1 in constitutive activation of epidermal growth factor receptor expression, nuclear factor-κB and stress-activated protein kinase. J Immunol, 160, 11161121.
  • Huen DS, Henderson SA, Croom-Carter D and Rowe M (1995) The Epstein–Barr virus latent membrane protein-1 (LMP1) mediates activation of NF-κB and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain. Oncogene, 10, 549560.
  • Ihle JN, Witthuhn BA, Quelle FW, Yamamoto K and Silvennoinen O (1995) Signaling through the hematopoietic cytokine receptors. Annu Rev Immunol, 13, 369398.
  • Ivashkiv LB (1995) Cytokines and STATs: how can signals achieve specificity? Immunity, 3, 14.
  • Izumi KM and Kieff ED (1997) The Epstein–Barr virus oncogene product latent membrane protein 1 engages the tumor necrosis factor receptor-associated death domain protein to mediate B lymphocyte growth transformation and activate NF-κB. Proc Natl Acad Sci USA, 94, 1259212597.
  • Izumi KM, Kaye KM and Kieff ED (1997) The Epstein–Barr virus LMP1 amino acid sequence that engages tumor necrosis factor receptor associated factors is critical for primary B lymphocyte growth transformation. Proc Natl Acad Sci USA, 94, 14471452.
  • Karras JG, Wang Z, Huo L, Frank DA and Rothstein TL (1997) Induction of STAT protein signaling through the CD40 receptor in B lymphocytes: distinct STAT activation following surface Ig and CD40 receptor engagement. J Immunol, 159, 43504355.
  • Kawahara A, Minami Y, Miyazaki T, Ihle JN and Taniguchi T (1995) Critical role of the interleukin 2 (IL-2) receptor γ-chain-associated Jak3 in the IL-2-induced c-fos and c-myc, but not bcl-2, gene induction. Proc Natl Acad Sci USA, 92, 87248728.
  • Kaye KM, Izumi KM and Kieff E (1993) Epstein–Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proc Natl Acad Sci USA, 90, 91509154.
  • Kaye KM, Izumi KM, Mosialos G and Kieff E (1995) The Epstein–Barr virus LMP1 cytoplasmic carboxy terminus is essential forB-lymphocyte transformation; fibroblast cocultivation complements a critical function within the terminal 155 residues. J Virol, 69, 675683.
  • Kieff E (1996) Epstein–Barr virus and its replication. In Fields,B.N., Knipe,D.M., Howley,P.M., Chanock,R.M., Monath,T.P., Melnick,J.L., Roizman,B. and Straus,S.E. (eds), Virology. 3rd edn. Lippincott–Raven Publishers, Philadelphia, PA, pp. 23432396.
  • Kieser A, Kilger E, Gires O, Ueffing M, Kolch W and Hammerschmidt W (1997) Epstein–Barr virus latent membrane protein-1 triggers AP-1 activity via the c-Jun N-terminal kinase cascade. EMBO J, 16, 64786485.
  • Kieser A, Kaiser C and Hammerschmidt W (1999) LMP1 signal transduction differs substantially from TNF receptor 1 signaling in the molecular functions of TRADD and TRAF2. EMBO J, 18, 25112521.
  • Kilger E, Kieser A, Baumann M and Hammerschmidt W (1998) Epstein–Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor. EMBO J, 17, 17001709.
  • Laherty CD, Hu HM, Opipari AW, Wang F and Dixit VM (1992) The Epstein–Barr virus LMP1 gene product induces A20 zinc finger protein expression by activating nuclear factor κB. J Biol Chem, 267, 2415724160.
  • Leonard W and O'Shea J (1998) JAKs and STATs: Biological Implications. Annu Rev Immunol, 16, 293322.
  • Liebowitz D, Wang D and Kieff E (1986) Orientation and patching of the latent infection membrane protein encoded by Epstein–Barr virus. J Virol, 58, 233237.
  • Macchi P et al. (1995) Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature, 377, 6568.
  • Miller WE, Mosialos G, Kieff E and Raab-Traub N (1997) Epstein–Barr virus LMP1 induction of the epidermal growth factor receptor is mediated through a TRAF signaling pathway distinct from NF-κB activation. J Virol, 71, 586594.
  • Mitchell T and Sugden B (1995) Stimulation of NF-κB-mediated transcription by mutant derivatives of the latent membrane protein of Epstein–Barr virus. J Virol, 69, 29682976.
  • Moorthy RK and Thorley-Lawson DA (1993) All three domains of the Epstein–Barr virus-encoded latent membrane protein LMP-1 are required for transformation of rat-1 fibroblasts. J Virol, 67, 16381646.
  • Mosialos G, Birkenbach M, Yalamanchili R, VanArsdale T, Ware C and Kieff E (1995) The Epstein–Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell, 80, 389399.
  • Murakami M, Narazaki M, Hibi M, Yawata H, Yasukawa K, Hamaguchi M, Taga T and Kishimoto T (1991) Critical cytoplasmic region of the interleukin 6 signal transducer gp130 is conserved in the cytokine receptor family. Proc Natl Acad Sci USA, 88, 1134911353.
  • Murata T and Puri RK (1997) Comparison of IL-13- and IL-4-induced signaling in EBV-immortalized human B cells. Cell Immunol, 175, 3340.
  • Rodriguez Tarduchy G, Collins M and Lopez Rivas A (1990) Regulation of apoptosis in interleukin-3-dependent hemopoietic cells by interleukin-3 and calcium ionophores. EMBO J, 9, 29973002.
  • Russell SM et al. (1995) Mutation of JAK3 in a patient with SCID: essential role of JAK3 in lymphoid development. Science, 270, 797800.
  • Sadowski HB, Shuai K, Darnell JE,Jr and Gilman MZ (1993) A common nuclear signal transduction pathway activated by growth factor and cytokine receptors. Science, 261, 17391744.
  • Sandberg M, Hammerschmidt W and Sugden B (1997) Characterization of LMP-1's association with TRAF1, TRAF2 and TRAF3. J Virol, 71, 46494656.
  • Schindler C, Shuai K, Prezioso VR and Darnell JE,Jr (1992) Interferon-dependent tyrosine phosphorylation of a latent cytoplasmic transcription factor. Science, 257, 809813.
  • Silvennoinen O, Ihle JN, Schlessinger J and Levy DE (1993) Interferon-induced nuclear signalling by Jak protein tyrosine kinases. Nature, 366, 583585.
  • Tomkinson B, Robertson E and Kieff E (1993) Epstein–Barr virus nuclear proteins EBNA-3A and EBNA-3C are essential forB-lymphocyte growth transformation. J Virol, 67, 20142025.
  • Tortolani PJ et al. (1995) Regulation of JAK3 expression and activation in human B cells and B cell malignancies. J Immunol, 155, 52205226.
  • Tosato G, Tanner J, Jones KD, Revel M and Pike SE (1990) Identification of interleukin-6 as an autocrine growth factor for Epstein–Barr virus-immortalized B cells. J Virol, 64, 30333041.
  • Wang D, Liebowitz D and Kieff E (1985) An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell, 43, 831840.
  • Wang F, Gregory C, Sample C, Rowe M, Liebowitz D, Murray R, Rickinson A and Kieff E (1990) Epstein–Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. J Virol, 64, 23092318.
  • Weber-Nordt RM, Egen C, Wehinger J, Ludwig W, Gouilleux-Gruart V, Mertelsmann R and Finke J (1996) Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein–Barr virus (EBV)-related lymphoma cell lines. Blood, 88, 809816.
  • Witthuhn BA, Silvennoinen O, Miura O, Lai KS, Cwik C, Liu ET and Ihle JN (1994) Involvement of the Jak-3 Janus kinase in signalling by interleukins 2 and 4 in lymphoid and myeloid cells. Nature, 370, 153157.
  • Xu X, Kang SH, Heidenreich O, Okerholm M, O'Shea JJ and Nerenberg MI (1995) Constitutive activation of different Jak tyrosine kinases in human T cell leukemia virus type 1 (HTLV-1) tax protein or virus-transformed cells. J Clin Invest, 96, 15481555.
  • Yates JL, Warren N and Sugden B (1985) Stable replication of plasmids derived from Epstein–Barr virus in various mammalian cells. Nature, 313, 812815.
  • Zimber-Strobl U, Kempkes B, Marschall G, Zeidler R, Van Kooten C, Banchereau J, Bornkamm GW and Hammerschmidt W (1996) Epstein–Barr virus latent membrane protein (LMP1) is not sufficient to maintain proliferation of B-cells but both it and activated CD40 can prolong their survival. EMBO J, 15, 70707078.